Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma – toxicity and efficacy
P Hau, T Jauch, U Baumgart, D Beier, S Gänßbauer, M Glas, B Hirschmann, H Koch, C Wismeth, A Steinbrecher, U Bogdahn · Aktuelle Neurologie · 2005 · Heft 10
Bibliografische Angaben
Zusammenfassung
Introduction: Temozolomide (Temodarä, TMZ) recently showed promising efficacy in an EORTC trial on first-line therapy of glioblastoma (Stupp R, 2005). Pegylated liposomal doxorubicin (Caelyxä, PEG-DOX) was evaluated in patients with recurrent high-grade glioma and showed an overall response rate of 40% (Hau P, 2002). Therefore, a combination of both agents seems promising. Methods: TMZ was given orally 75mg/m2 daily during standard radiotherapy (initiation) and 150–200mg/m2 days 1–5 in 28 days starting 4 weeks after radiotherapy (maintainance). PEG-DOX was given as a short-time infusion in a dose-escalation regi…
